Michael Okunewitch
Stock Analyst at Maxim Group
(1.61)
# 3,229
Out of 4,876 analysts
26
Total ratings
29.17%
Success rate
-9.76%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $4.23 | +727.42% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $3.50 | - | 2 | May 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Maintains: Buy | $6 → $3 | $1.42 | +111.27% | 2 | May 15, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.70 | +155.32% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.19 | +486.46% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.40 | +900.00% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.96 | +211.11% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.03 | +288.35% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.71 | +1,585.39% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.30 | +361.54% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.86 | +1,296.00% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.31 | +1,732.06% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $3.02 | +495.99% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.92 | +69,249.32% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $19.43 | +28.67% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.67 | +259.28% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.25 | +1,013.59% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.33 | +7,418.80% | 1 | Nov 30, 2021 |
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $4.23
Upside: +727.42%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.50
Upside: -
Anebulo Pharmaceuticals
May 15, 2025
Maintains: Buy
Price Target: $6 → $3
Current: $1.42
Upside: +111.27%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.70
Upside: +155.32%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.19
Upside: +486.46%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.40
Upside: +900.00%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.96
Upside: +211.11%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.03
Upside: +288.35%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.71
Upside: +1,585.39%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.30
Upside: +361.54%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.86
Upside: +1,296.00%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.31
Upside: +1,732.06%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.02
Upside: +495.99%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.92
Upside: +69,249.32%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $19.43
Upside: +28.67%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.67
Upside: +259.28%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $2.25
Upside: +1,013.59%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.33
Upside: +7,418.80%